The potential drug–drug interaction between proton pump inhibitors and warfarin

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 12, 2015, Pages 1337-1340

  Henriksen, Daniel Pilsgaard ^a   Stage, Tore Bjerregaard ^b   Hansen, Morten Rix ^a,b   Rasmussen, Lotte ^b   Damkier, Per ^a,b   Pottegård, Anton ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

adverse drug reactions; drug interactions; pharmacoepidemiology; proton pump inhibitors; vitamin K antagonists

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; WARFARIN;

ADULT; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENCY; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTPATIENT DEPARTMENT; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL;

EID: 85027948084     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3881     Document Type: Article

References (15)

1. Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 2013; 34: 1708–1713. doi:10.1093/eurheartj/eht042.
2. Shaheen NJ, Hansen RA, Morgan DR, et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006; 101: 2128–2138. doi:10.1111/j.1572-0241.2006.00723.x.
3. Julkunen RJ. The absorption of warfarin from the rat stomach in situ. Med Biol 1976; 54: 260–263.
4. Cadiou G, Varin R, Levesque H, et al. Risk factors of vitamin K antagonist overcoagulation. A case–control study in unselected patients referred to an emergency department. Thromb Haemost 2008; 100: 685–692.
5. Teichert M, van Noord C, Uitterlinden AG, et al. Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment: interaction between proton pump inhibitors and acenocoumarol. Br J Haematol 2011; 153: 379–385. doi:10.1111/j.1365-2141.2011.08633.x.
6. Li X-Q, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32: 821–827.
7. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006; 29: 769–784.
8. Limdi NA, Veenstra DL. Warfarin pharmacogenetics. Pharmacotherapy 2008; 28: 1084–1097. doi:10.1592/phco.28.9.1084.
9. Pottegård A, dePont CR, Wang SV, Gagne JJ, Larsen TB, Hallas J. Pharmacoepidemiological assessment of drug interactions with vitamin K antagonists: drug interactions with vitamin K antagonists. Pharmacoepidemiol Drug Saf 2014; 23: 1160–1167. doi:10.1002/pds.3714.
10. Hallas J. Conducting pharmacoepidemiologic research in Denmark. Pharmacoepidemiol Drug Saf 2001; 10: 619. doi:10.1002/pds.638.
11. Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011; 39: 22–25. doi:10.1177/1403494810387965.
12. Kuo RN, Dong Y-H, Liu J-P, Chang C-H, Shau W-Y, Lai M-S. Predicting healthcare utilization using a pharmacy-based metric with the WHO's anatomic therapeutic chemical algorithm. Med Care 2011; 49: 1031–1039.
13. Thygesen LC, Daasnes C, Thaulow I, Bronnum-Hansen H. Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scand J Public Health 2011; 39: 12–16. doi:10.1177/1403494811399956.
14. Pottegård A, Henriksen DP, Madsen KG, Hellfritzsch M, Damkier P, Stage TB. Change in international normalized ratio among patients treated with dicloxacillin and vitamin K antagonists. JAMA 2015; 314: 296. doi:10.1001/jama.2015.6669.
15. Duursema L, Muller FO, Schall R, et al. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin [see comments]. Br J Clin Pharmacol 1995; 39: 700–703.